Special Issue "Anaplastic Lymphoma Kinase-Related Cancers: Biological and Therapeutic Implications"
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: closed (30 March 2019).
Interests: anaplastic lymphoma kinase; anaplastic large cell lymphoma (ALCL); NPM-ALK, non-coding RNA, microRNA, DNA methylation, mouse model
Anaplastic lymphoma kinase (ALK) is associated with oncogenesis in different cancers, such as anaplastic large cell lymphoma, lung cancer, neuroblastoma, and breast cancer, by abnormal fusion of ALK, ALK amplification or overexpression. The full-length ALK receptor tyrosine kinase is a receptor tyrosine kinase, which participates in embryonic nervous system development, but its expression decreases after birth. Upon ligand binding to the extracellular domain, the receptor undergoes dimerization and subsequent autophosphorylation of the intracellular kinase domain. In recent years, ALK inhibitors have been developed for cancer treatment. Tyrosine Kinase inhibitors (TKI) are directed against the ATP-binding site of the catalytic domain, which is highly conserved in ALK. However, the presence of different ALK fusions and also point mutations confer different sensitivity to ALK inhibitors and inevitably drug resistance emerge within a few years in most cases. New strategies are underway to overcome the limitations of current ALK inhibitors.
This Special Issue “Anaplastic Lymphoma Kinase-Related Cancers” will cover a selection of recent research topics and current review articles in the field of ALK. Experimental papers, up-to-date review articles, and commentaries are all welcome highlighting anaplastic large cell lymphoma, lung cancer neuroblastoma and breast cancers.
Dr. Fabienne Meggetto
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Physiological function
- ALK-expressing cancers
- Molecular pathway, including non-coding RNA
- Genomic and epigenetic alterations
- Immune response
- Therapeutic pathway
- Clinical resistance